News
Academy
Editorial PodcastsEditorial VideosPeer ExchangeProfiles in Medicine
Conference CoverageConference Listing
Pharmaceutical Executive
Partner Perspectives
Content Engagement HubsE-BooksEventsSponsored PodcastsSponsored VideosWebcastsWhitepapers
Subscribe
Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
Spotlight -
  • Latest Executive Roundtables
  • Asembia 2025
  • Sales Effectiveness
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

Corporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate CommunicationsCorporate Communications
Direct-to-ConsumerDirect-to-ConsumerDirect-to-ConsumerDirect-to-Consumer
Emerging BiopharmaEmerging BiopharmaEmerging Biopharma
IR Licensing and PartnershipsIR Licensing and PartnershipsIR Licensing and Partnerships
Market AccessMarket AccessMarket AccessMarket Access
Medical AffairsMedical AffairsMedical AffairsMedical Affairs
OperationsOperationsOperationsOperationsOperations
Patient EngagementPatient Engagement
RegulatoryRegulatoryRegulatoryRegulatory
Sales & MarketingSales & MarketingSales & MarketingSales & MarketingSales & Marketing
IS1
  • Applied Clinical Trials

  • BioPharm International

  • Cannabis Science and Technology

  • Chromatography Online

  • Nutritional Outlook

  • Pharmaceutical Commerce

  • Pharmaceutical Executive

  • Pharm Tech

  • Spectroscopy Online

  • Turbo Machinery Magazine

    • Academy
    • Partner Perspectives
    • Subscribe
Advertisement

Feature

Article

October 2, 2023

Navigating Health Insurance Coverage for Innovative and Specialty Drugs: Q&A With Maria Kirsch, President of Patients Services at EVERSANA

Author(s):

Mike Hollan

Kirsch discusses the complexity of the drugs and the verification process, along with EVERSANA’s new platform, ACTICS eAccess.

Maria Kirsch

Maria Kirsch
President, patient services
EVERSANA

EVERSANA recently launched its ACTICS eAccess solution, a platform designed to improve patient access to therapy. Maria Kirsch, president of patient services at EVERSANA, spoke with Pharmaceutical Executive about this new platform and market conditions that led to its creation.

Pharmaceutical Executive: How are current eBV and ePA tools failing to meet the needs of patients?

Maria Kirsch: Medical benefit verification and expertise have long been considered the most complex arena to navigate for patients and health care providers (HCPs), and drug coverage is only one small element of the equation.

The traditional approach to verify this information for patients requires phone calls. Through ACTICS eAccess’ insight into major medical plans, patients and providers can determine patient specific out-of-pocket costs, patient deductibles, and coverage for physician administered drugs, buy and bill as well as ancillary services. Importantly, providers can compare coverage and out-of-pocket costs between pharmacy and medical to identify the best reimbursement pathway for the patient. Finally, next-generation technology expedites the prior authorization submission process, delivering a much higher percentage of accepted submissions by insurance providers.

The old process can be very time-consuming, lasting upwards of 45 minutes to an hour. It can require calls to multiple payers to get insight into medical and pharmacy coverage. Finally, these calls are often required for an individual patient multiple times per year. In the past few years, electronic benefits verification (eBV) tools have evolved to close this gap, but the success rate for an accurate estimate of a patient’s financial responsibility is at best 60%. Why? Most tools today rely on algorithms for estimation. Similarly, with electronic prior authorization (ePA) solutions, some 70% of submissions are rejected with little or no status for patients.

This high rate of inaccuracy has resulted in financial barriers for patients, increased burdens on Patient Assistance Programs and Hubs, and hesitance among HCPs to prescribe therapy. It’s challenging for everyone, and we need to do better.

PE: How does technology like the ACTICS® eAccess platform solve these issues?

Kirsch: At EVERSANA, we have always said since day one that patients are at the center of everything we do. We firmly believe this, and especially on my team that works with patients day in and day out, we needed to do more.

We have invested in both technology and the digital connectivity we have with more than 1,400 payers across the U.S. to solve these challenges.

ACTICS eAccess is that solution that integrates data from more than 90% of covered lives to verify pharmacy and major medical plan coverage nearly immediately, within seconds.

From here, patients (and their physicians) can quickly see out-of-pocket costs, patient deductibles, and coverage for physician-administered drugs, buy and bill as well as ancillary services. Doctors can compare coverage and out-of-pocket costs between pharmacy and medical to identify the best reimbursement pathway for the patient. And on top of it all, our technology expedites the prior authorization submission process, delivering a much higher percentage of accepted submissions by insurance providers.

For patients, it is as simple as entering five fields into a branded website, and within seconds they know what to expect. We have narrowed the funnel to improve access and help more people get on therapy faster.

PE: Will this make it easier for patients and doctors to connect?

Kirsch: Without a doubt, this technology will drastically make life better for doctors and patients by providing a tool they can use at the site of care. Presenting patients with affordable treatment options and necessary out-of-pocket costs during their doctor’s visit not only expedites treatment initiation but creates a level of trust and confidence that cannot be delivered over the phone days after the initial appointment. 

Through this information, both patients and doctors will know what is ahead, and be able to have clearer, more detailed discussions that will result in better outcomes.

PE: Will this help patients find affordable care easier?

Kirsch:Through the ability of ACTIS eAccess to compare out-of-pocket costs between pharmacy and medical, patients will be able to find the best path to care while also seeing the most affordable option. The tool also has the capabilities to help patients learn if they are eligible for a Patient Assistance Program, along with necessary steps to enroll. This obviously comes with other variables including a patient’s perception of a clinician or program, but what ACTICS eAccess has done is open blinds and show both doctors and patients exactly what they need to know to move forward with care.

PE: Can this solution fit into existing patient services programs?

Kirsch:The beauty of what we have built is scalable. We can plug into existing patient support hubs, offer this as a standalone verification tool, integrate the software into patient and HCP-facing websites or add it to an HCP portal. We can do programs of all sizes and the data is unmatched through EVERSANA’s relationships with nearly every insurance payer in the U.S.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!
Related Videos
Gen Li
Robert Lisicki
Gen Li
Gen Li
Dr. Ben Zeskind
Gen Li
Dr. Ben Zeskind
Gen Li
Related Content
Advertisement
MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery
August 5th 2025

MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery

Don Tracy, Associate Editor
The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s DA-1241 following promising Phase IIa trial (NCT06054815) results in patients with presumed metabolic dysfunction-associated steatohepatitis.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 5th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma
August 5th 2025

FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma

Don Tracy, Associate Editor
The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed that patients treated with Breyanzi for relapsed or refractory marginal zone lymphoma demonstrated strong and lasting responses.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 5th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Site Logo
August 5th 2025

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Karla Anderson, Partner, Guidehouse Jacob Graham, Partner, Guidehouse Cavay Ip, Director, Guidehouse
Site Logo
August 5th 2025

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Hemal Somaiya, Chief Strategy Officer, PharmaForceIQ
Related Content
Advertisement
MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery
August 5th 2025

MetaVia, Syntekabio Partner to Expand Indications for Oral MASH Drug Using AI Drug Discovery

Don Tracy, Associate Editor
The AI-driven collaboration will use Syntekabio’s DeepMatcher platform to identify new therapeutic targets for MetaVia’s DA-1241 following promising Phase IIa trial (NCT06054815) results in patients with presumed metabolic dysfunction-associated steatohepatitis.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
August 5th 2025

Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research

Miranda Schmalfuhs
LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma
August 5th 2025

FDA Grants Priority Review to Bristol Myers Squibb’s Breyanzi in Relapsed or Refractory Marginal Zone Lymphoma

Don Tracy, Associate Editor
The supplemental New Drug Application is supported by data from the Phase II TRANSCEND FL trial (NCT04245839), which showed that patients treated with Breyanzi for relapsed or refractory marginal zone lymphoma demonstrated strong and lasting responses.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
August 5th 2025

Beyond the Prescription: Pharma's Role in Digital Health Conversations

Canopy
Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Site Logo
August 5th 2025

From Blockbusters to Black Holes: Pharma Launch Strategy in the Age of Technology and AI

Karla Anderson, Partner, Guidehouse Jacob Graham, Partner, Guidehouse Cavay Ip, Director, Guidehouse
Site Logo
August 5th 2025

Strategic advantage: Optichannel engagement drives ROI across the product lifecycle

Hemal Somaiya, Chief Strategy Officer, PharmaForceIQ
About
Advertise
Contact Us
Editorial Board
Editorial Submission Guidelines
Do Not Sell My Personal Information
Privacy Policy
Terms and Conditions
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.